← Back to headlines
Merck Nears $6 Billion Acquisition of Terns Pharma for Cancer Portfolio
Merck is reportedly close to a $6 billion acquisition of Terns Pharma, aiming to boost its cancer drug pipeline following promising clinical data on a bone and blood cancer treatment.
25 Mar, 00:59 — 25 Mar, 04:12
The Story
Analyzing sources…
Source Diversity
Source Diversity
Moderate (46/100)3 sources25/33
Spectrum spread— 2/5 buckets covered8/33
Far L
Left
Center2
Center (2)
ReutersFT
Right1
Right (1)
seeking-alpha
Far R
Geographic diversity— 3 regions13/34
US1Intl1UK1
Sources
Showing 3 of 3 sources
ReutersVery High5h ago
Merck nears $6 billion acquisition of Terns Pharma to boost cancer portfolio, FT reports - Reuters
Merck nears $6 billion acquisition of Terns Pharma to boost cancer portfolio, FT reports Reuters
Read full article →FTVery High5h ago
Merck nears $6bn biotech deal to boost cancer drug pipeline
Terns Pharma stock has jumped since promising clinical data on its bone and blood cancer treatment last year
Read full article →seeking-alphaMixed2h ago
Merck close to $6B acquisition of Terns Pharma to boost cancer portfolio: FT
Read full article →Coverage Timeline
First report: FT · 25 Mar, 00:59|Full coverage: 3 · 3h|Window: 3h
Left-leaningCenterRight-leaning
Related Stories
Philippines Declares National Energy Emergency; Fuel Rationing Eyed Amid Dwindling Supplies
just now
Fuel hikes hit Zambales fishers in West Philippine Sea
just now
Philippine President Marcos Approves Emergency Fuel Fund and Reviews China Ties Amid Energy Crisis
just now
Perplexity CEO Aravind Srinivas Optimistic About AI's Impact on Jobs
12m ago